WeightWatchers partners with LillyDirect to expand Med+ nationwide

WW International, the company once known simply as WeightWatchers, has expanded its Med+ clinical program nationwide through a partnership with LillyDirect, Eli Lilly's direct-to-consumer pharmacy channel ^[1]. The move deepens a pivot that began after the company's 2025 Chapter 11 bankruptcy, in which WW shed the debt-heavy legacy behavioral business in favor of a model built around prescribing and dispensing GLP-1 medications ^[1].

The numbers show why the company is leaning into this shift. Second-quarter 2026 revenue fell 22.7% year over year, driven by decline in WW's traditional coaching and meeting-based membership, while the clinical segment tied to GLP-1 prescribing grew 30.4% ^[1]. The bankruptcy restructuring eliminated more than $1.1 billion in debt and cut WW's term loan from $1.6 billion to $423.6 million, leaving the company with $101.5 million in unrestricted cash ^[1]. WW's Core+ behavioral tier also posted its third straight quarter of subscriber growth, and about 20,000 members upgraded from behavioral to clinical membership in the first quarter of 2026, a shift the company says quadrupled average revenue per user ^[1].

As of September 5, 2026, Med+ membership costs $25 a month for the first two months on a 12-month plan, then $74 a month, with medication billed separately ^[2]. That introductory rate is set to end September 8, 2026 ^[2]. WW prescribes only FDA-approved brand medications: Wegovy injection and pill, Zepbound, Saxenda, the Foundayo pill, metformin, and naltrexone/bupropion, dispensed through its mail-order pharmacy partner Carepoint in Illinois ^[2]. The company has not sold compounded semaglutide or tirzepatide since around May 2025, after federal shortage declarations for both drugs were lifted ^[2]. Through LillyDirect, cash-pay Zepbound runs $299, $399, or $449 a month depending on dose, and Wegovy's pen starts at an introductory $199 before rising to $349 ^[2].

Why it matters for patients

For people considering or already using Med+, the LillyDirect expansion mainly changes reach and logistics, not the underlying drugs or their effects. WW reports that Med+ members on a GLP-1 lost an average of 21% of body weight at 12 months, based on company data from roughly 3,250 patients that has not been peer reviewed, a figure that lines up with the 20.9% mean weight loss Zepbound's own label reports at 72 weeks on the 15 mg dose in its pivotal trial ^[2]. That similarity suggests the medication itself, not WW's coaching, is doing most of the work in that comparison, since there is no control group in WW's figure ^[2].

Cost remains a real variable. WW's insurance coordinators work with commercial insurance plans only, not Medicare, Medicaid, or Kaiser, so many members are paying cash for both the membership fee and the medication ^[2]. Separately, WW has a Medicare GLP-1 Bridge program offering $50-a-month access to select medications from July 1, 2026 through December 31, 2027, which operates apart from Med+ ^[2]. Patients weighing WW against other telehealth options should also note that WW does not offer compounded GLP-1s, unlike some competitors, which affects both price and the range of formulations available ^[2].

What happens next

WW's introductory Med+ pricing is scheduled to end September 8, 2026 ^[2]. The company also named Stephen Bye as its new president and CEO on September 9, 2026, following the March 2026 departure of former CEO Tara Comonte, a leadership transition that could shape how aggressively WW continues its clinical pivot ^[1]. The Medicare GLP-1 Bridge program is set to run through the end of 2027, offering a longer-term test of how WW serves patients outside commercial insurance ^[2].